CORONA - ViKon - Targeted elimination of SARS-CoV-2 by microparticle-based high-affinity Visrus binding conjugates; subproject 1: ViKon HKI.
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 03COV17A
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$1,322,159.72Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
Axel BrakhageResearch Location
GermanyLead Research Institution
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-InstitutResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
In this subproject, basic principles will be established and input materials provided to enable selective addressing of the SARS-CoV-2 pathogen and its effective, therapeutically efficient elimination by endogenous processes. A variant of the ACE2 receptor domain that is competitive with the native sequence will be identified (WP1), a bioorthogonal linkage method will be established (WP3), biophysical assays for at least four surface peptides will be performed (WP4), and exposure data for at least one frontrunner nanoparticle drug will be generated in a rodent model (WP5).